Fig. 9: Schematic summary of the findings in this study. | Nature Communications

Fig. 9: Schematic summary of the findings in this study.

From: Receptor-interacting protein kinase 2 (RIPK2) stabilizes c-Myc and is a therapeutic target in prostate cancer metastasis

Fig. 9

RIPK2 binds to MKK7 and activates the MKK7(/JNK)/c-Myc phosphorylation cascades, thereby stabilizing the c-Myc oncoprotein and enhancing c-Myc activity, which is required for PC metastasis. The non-canonical RIPK2/MKK7/c-Myc signaling pathways can be blocked by genetic or pharmacological inhibition of RIPK2, resulting in the proteasomal degradation of c-Myc and the inhibition of c-Myc activity and PC metastasis. Of clinical relevance, RIPK2 and MYC are frequently co-amplified/gained in PC and several other cancer types, and their activity scores are strongly correlated across many cancers. Created with BioRender.com.

Back to article page